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Abstract
Molecular imaging allows clinicians to visualize the progression of tumours and obtain relevant
information for patient diagnosis and treatment1. Owing to their intrinsic optical, electrical and
magnetic properties, nanoparticles are promising contrast agents for imaging dynamic molecular
and cellular processes such as protein-protein interactions, enzyme activity or gene expression2.
Until now, nanoparticles have been engineered with targeting ligands such as antibodies and
peptides to improve tumour specificity and uptake. However, excessive loading of ligands can
reduce the targeting capabilities of the ligand3,4,5 and reduce the ability of the nanoparticle to bind
to a finite number of receptors on cells6. Increasing the number of nanoparticles delivered to cells
by each targeting molecule would lead to higher signal-to-noise ratios and improve image
contrast. Here, we show that M13 filamentous bacteriophage can be used as a scaffold to display
targeting ligands and multiple nanoparticles for magnetic resonance imaging of cancer cells and
tumours in mice. Monodisperse iron oxide magnetic nanoparticles assemble along the M13 coat,
and its distal end is engineered to display a peptide that targets SPARC glycoprotein, which is
overexpressed in various cancers. Compared with nanoparticles that are directly functionalized
with targeting peptides, our approach improves contrast because each SPARC-targeting molecule
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delivers a large number of nanoparticles into the cells. Moreover, the targeting ligand and
nanoparticles could be easily exchanged for others, making this platform attractive for in vivo
high-throughput screening and molecular detection.
M13 is a filamentous virus with five genetically modifiable coat proteins (p3, p6, p7, p8, and
p9) for peptide or protein display. Previously, phage display has been exploited for epitope
discovery7, gene delivery8, antibody delivery9, and in vitro and in vivo ligand
discovery10,11. Although phage display allows rapid, amplifiable screening of lead
molecules for targeting, the genetic and physical properties of M13 also make it an excellent
biological building block for bottom-up fabrication and assembly of materials12. The highly
ordered structure of the 2700 copies of the major coat protein p8 and the filamentous shape
of M13 (~6.5 nm in diameter and ~880 nm in length) allows the phage to multivalently
interact with nanomaterials. Our lab has engineered M13 for display of material-specific
peptides on p3 and p8 as a template to grow and nucleate various inorganic materials for
applications including high power Li ion batteries and photocatalytic water splitting13,14.
Here, we extend this work and report the development of M13 bacteriophage as a vector
incorporating a tumour-targeting peptide15 and a peptide motif for templated assembly of
magnetic iron oxide nanoparticles (MNPs) towards nanoparticle-mediated, dark contrast-
based magnetic resonance imaging for specific tumour detection (Fig. 1a). We investigate
selective tumour targeting against prostate cancer xenograft models expressing different
levels of secreted protein, acidic and rich in cysteine (SPARC), which is upregulated in
various cancers (reviewed in 16) and correlated with poor prognosis16. The capsid
organization of M13 spatially separates targeting and imaging moieties, circumventing any
potential problems with ligand or probe functionality. Using p3 to display targeting ligands
while assembling multiple MNPs along the p8 capsid (Fig.1a) achieves targeting and
delivers a larger payload of MNPs per SPARC compared with directly functionalized
nanoparticles.
Previously, we engineered multiple glutamic acid residues on the N-terminus of the major
coat capsid protein p8 on M13 for assembly of various metal oxides for anode battery and
layer-by-layer polymer assembly applications17. At physiological pH, the triglutamate
peptide-modified M13 has a net negative charge, allowing for electrostatic assembly with
positively charged moieties, such as positively charged nanoparticles17. Further, to create a
molecularly targeted M13, a SPARC-binding peptide (SPPTGIN, designated as SBP)
identified using phage display15 was genetically engineered into the p3 minor coat protein of
triglutamate modified M13 (Fig. 1a); in the presence of MNPs, the resulting phage is
designated as M13-SBP-MNP.
We then synthesized crystalline, monodisperse iron oxide nanoparticles to assemble along
the modified M13 (Fig. 2 and Supplementary Note 1). We confirmed the monodispersity by
transmission electron microscopy (TEM) and dynamic light scattering (DLS, Fig. 2). From
high-resolution TEM, the particles demonstrated distinct lattice fringe patterns, suggesting a
highly crystalline structure (Fig. 2, top row, left column, inset). X-ray diffraction confirmed
the cubic spinel structure of the iron oxide nanoparticles, whereas a d-spacing comparison
corroborated previous reports that iron oxide particles are either maghemite (γ-Fe2O3) or
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magnetite (Fe3O4)18 (Supplementary Fig. S1 and Table S1). These particles were water-
solubilized with a PEG-lipid formulation (Supplementary Note 1) and were stable in water
for at least two months (Supplementary Fig. S2).
We characterized the assembly of the nanoparticles along the coat of M13. MNPs were
mixed with M13-expressing triglutamate motif and allowed to assemble along the length of
the virus. TEM confirmed multivalent MNP assembly along the virus (Fig. 2, top row, right
column). Previous work has shown M13-templated materials with and without engineered
p3 ligands have similar materials properties13. MNPs are aligned in a filamentous
orientation along the p8 coat with a length of approximately ~ 800 nm, which is the
approximate length of M13. The number of MNPs per M13 was quantified by iron content
using inductive coupled plasma atomic emission spectroscopy (ICP-AES) (Supplementary
Note 2). Using iron standards, we measured the emission intensities and made a calibration
curve (Supplementary Fig. S3) to interpolate iron content of M13-templated MNPs from
measured intensities and calculate the number of MNPs per virus. There are approximately
26 particles per M13, confirming multivalent assembly as observed by TEM. From dynamic
light scattering, M13 and M13-assembled MNPs are monodisperse, with a radius of ~147.3
nm (Supplementary Fig. S4) and ~181.4 nm (Fig. 2, bottom row, right column),
respectively. Importantly, M13-assembled MNPs have a single histogram population and
lack multiple peaks, suggesting the nanoparticles stably complex with the virus and do not
aggregate into multiple populations. The increase in size of M13-MNP compared with M13
can be attributed to multiple MNPs assembling on the 2700 p8 copies. M13-MNP is stable
in other biological solutions including PBS (Supplementary Note 3 and Supplementary Fig.
S5), culture media and serum for at least three weeks (Fig. 2) and is not cytotoxic by
standard WST-1 cell proliferation assay (Supplementary Fig. S6). Virus-nanoparticle
complexes are stable and non-toxic in physiological conditions, which makes them attractive
for in vivo imaging.
To investigate the magnetic resonance (MR) contrast potential of MNPs and M13-MNPs,
we measured the transverse relaxation (T2). Proton relaxivity is a rate of proton relaxation in
response to iron atom concentration. Paramagnetic iron oxide nanoparticles cause local
inhomogenities in the magnetic field resulting in decoherence of the water proton precession
of the spins. The resulting relaxation of the spins until the magnetization decays to zero
causes a negative, or ‘dark’ contrast in the background of the light MR image. We measured
the T2 of MNPs and M13-MNPs and determined relaxivity based on the iron concentration
of the MNPs (Table 1 and Supplementary Fig. S7). MNPs and M13-MNP had comparable
relaxivities of 65.1 mM−1 s−1 and 58.7 mM−1 s−1, respectively. Their relaxivities are an
improvement over those of several superparamagnetic iron oxide particles including
ferumoxtran and monocrystalline iron oxide nanoparticles (Table 1), which exhibit
relaxivities of 35.3 and 34.8 mM−1 s−1, respectively19,20. These clinically used particles
possess lower R2 relaxivities compared with our crystalline particles since they are
synthesized in aqueous media and thus have poorer crystallinity21. Ferumoxides including
Feridex (Table 1) demonstrate higher relaxivities (107 mM−1 s−1) than synthesized MNPs
and M13-MNP, probably a result of their multiple crystalline domains22. Nevertheless, the
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enhanced contrast properties of M13-MNP compared with several clinically used particles
highlight its potential as an in vivo imaging probe.
After we validated SPARC-binding peptide is displayed on M13 in the presence of MNPs
and targets SPARC-expressing C4-2B prostate cancer cell line (Supplementary Note 4 and
Supplementary Figs. S8 and S9), we investigated selectivity of targeting against cell lines
expressing different levels of SPARC. DU145 control (low SPARC expressing) and C4-2B
(higher level of SPARC expression) cell lines were incubated with M13-SBP-MNP at two
different virus concentrations and relaxation times were measured from harvested cell
lysates. At both concentrations, there was approximately a threefold decrease in relaxation
times of M13-SBP-MNP incubated C4-2B lysates when compared with DU145 cell lysates,
suggesting selective and specific uptake of M13-SBP-MNP (Fig. 1b). The increase in
targeting can be attributed to differences of cellular SPARC expression levels between
C4-2B and DU145 cells. From quantitative flow cytometry (Supplementary Note 5), we
determined C4-2B expressed 5870±565 SPARC molecules per cell, whereas DU145 had
3395±633 copies per cell (Supplementary Figs. S10 and S11). This suggests while C4-2B
expresses higher levels of SPARC in vitro compared with control DU145, there is SPARC
expression present in DU145 cells. It is important to note since SPARC is a matricellular
stromal protein, there will be differences between expression levels in cell lines and
tumours.
We next examined SPARC-targeted imaging of prostate cancer in vivo. C4-2B and DU145
cells were injected subcutaneously in immunodeficient mice and, on tumour formation,
M13-SBP-MNP was injected intravenously and allowed to circulate for 24 h. Mice with
tumours were scanned pre-injection and 24 h post-injection via a 7 T magnetic resonance
imaging (MRI) scanner with a T2*-weighted pulse sequence. Importantly, mice with C4-2B-
derived tumours demonstrated a decrease in MR signal 24 hours after injection of SPARC-
targeted phage (Fig. 3a,b). Mice bearing DU145 tumours had tumours that remained bright
after injection of contrast agent (Fig. 3c,d), indicating uptake of M13-SBP-MNP is specific
to C4-2B tumours. Pixel intensity due to iron uptake in the tumours was measured to
quantify dark contrast signal enhancement (Fig. 3e). Compared with DU145, there is an
approximately sixfold decrease in pixel intensity (per cm2) in C4-2B (Fig. 3e). The intensity
decrease implies there is a darkening of the MR signal in C4-2B owing to increased M13-
SBP-MNP uptake, compared with DU145 controls. We corroborated the imaging with
correlative histology. Tumour sections were stained with haematoxylin and eosin (H&E)
and Perl’s reagent for the presence of iron from MNPs. As expected from the MRI findings,
sections of tumour derived from C4-2B cells stained blue with Perl’s reagent (Fig. 3f, top
row, middle column), whereas DU145 tumours had little to no staining, indicating a lack of
iron present in the tumour (Fig. 3f, bottom row, middle column). Iron staining in the
extracellular matrix is present in areas of SPARC expression23 of C4-2B tumours (Fig. 3f,
top row, right column) whereas control DU145 tumours do not stain for SPARC expression,
which suggests uptake is specific to SPARC expression.
As previously mentioned, most work focuses upon functionalizing each nanoparticle with
multiple ligands to improve binding, but the number of cell surface targets and their
accessibility in cell lines and tumours limit targeting efficiency and subsequent delivery of
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these agents6. One approach to improve targeting of agents such as drugs and nanoparticles
is to develop carriers able to deliver multiple agents per receptor6. We investigated the
ability of M13 to deliver multiple MNPs per SPARC molecule for potential signal
amplification (Fig. 4a). C4-2B cells were incubated with either fluorescently tagged M13-
SBP-MNP or functionalized MNPs with equivalent amounts of targeting peptide to bind and
saturate SPARC, accounting for five peptides on p3 per M13 and four and eight peptides per
functionalized nanoparticles at the low and high densities, respectively. After 1 h, there is a
threefold increase in fluorescence with M13-SBP-MNP compared with MNPs
functionalized with the two different concentrations of SBP (Fig. 4b). The fluorescence of
M13-SBP-MNP uptake increases after 4 h, with a 11-fold improvement compared with
functionalised MNPs (Fig. 4b). To investigate the potential for enhanced contrast the T2
relaxation of incubated cell lysates was measured. There is a 18-fold decrease in relaxivity
per particle in lysates targeted with M13-SBP-MNP compared with low SBP-MNP (Fig.
4c), indicating greater delivery of MNPs using M13 improves the relaxation signal. These
results suggest M13 is an effective scaffold for amplified targeting in vitro and has the
potential to further enhance dark contrast imaging in vivo.
We have demonstrated M13 as a nanoscale scaffold that integrates phage-presenting
targeting ligands and nanoparticle assembly for molecularly targeted, amplified imaging of
prostate cancer. Our virus-nanoparticle complexes are stable and exhibit improved MR
contrast potential compared with several clinically used superparamagnetic iron oxide
particles. Recent work has reported MNPs with higher relaxivities, obtained by altering the
composition through doping24 or oxidation25. These synthesized particles could be
multivalently assembled using M13 scaffold for further signal enhancement. Using our
system, we demonstrate higher delivery of MNPs per target than traditional nanoparticle
approaches, and this novel targeting approach can be coupled with other amplification
strategies including bioorthogonal chemistries for pre-targeting26 or communicating
nanoparticle systems27 to further increase nanoparticle delivery. Interestingly, the low
number of SPARC binding peptide per M13 (~1 peptide per 5 nanoparticles) is almost
comparable to non-modified MNPs; regardless of this, M13 still achieves improved
targeting in vitro compared with peptide-functionalized MNPs (Fig. 4) and selective
targeting in vivo (Fig. 3). This highlights the potential of M13 as a carrier for effective
delivery without the need for high presentation of targeting ligands. Although previous
reports of in vivo phage targeting has focused on the vasculature11,28 and lymphatic
system29, homing to the tumour stroma suggests the ability of phage to penetrate into the
tumour. Future work will involve investigating mechanism of M13 tumour uptake in vivo.
As M13 can be easily genetically engineered for peptide display, numerous functionalities
can be encoded for incorporating other imaging moieties for multimodal imaging or possibly
chemotherapeutic agents for drug delivery and therapy. We have recently shown by re-
engineering the p9 coat protein of M13, we can incorporate and spatially control drugs
alongside imaging and targeting moieties (unpublished results). The genetic control and
modularity of the M13 platform make it a useful and powerful screening tool to identify
promising imaging agents for tumour detection and stratification and investigate other
diseases such as atherosclerosis30, beta cells in diabetes, as well as bacterial infections.
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Cell lines and culture
DU145 human prostate cancer cell lines were purchased from American Type Culture
Collection (ATCC). C4-2B cells were provided courtesy of Dr. Michael Weber (University
of Virginia). DU145 was grown in Dulbecco’s Minimum Essential Medium (DMEM)
supplemented with 10% FBS (Hyclone) and 1% penicillin/streptomycin (Life Technologies)
at 37°C in 5% CO2. C4-2B were grown in T-medium (Life Technologies) with 10% FBS
and pencillin/streptomycin (Life Technologies).
Complexation of M13 with MNPs
Molar excess of water-soluble, aminated iron oxide MNPs (synthesis described in
Supplementary Note 1) were mixed with M13 expressing triglutamate motif and optimized
to get ~26 nanoparticles per virus. Virus-MNP complexes were precipitated by standard
PEG/NaCl precipitation, thereby removing unbound, excess particles present the
supernatant. The virus-MNP complexes were resupsended in either water or PBS. The
number of MNPs per virus was quantified by measuring iron content using ICP-AES
spectroscopy (see Supplementary Note 2), interpolating the amount of iron in the sample
against a standard curve and calculating the number of iron oxide particles per virus.
TEM and HRTEM of iron oxide MNPs and M13-templated MNPs
For high-resolution transmission electron microscopy, JEOL 2010F TEM was used. For
TEM analysis, MNPs and virus-templated MNPs solutions were dropped on carbon copper
holey grid (Ted Pella), washed with ddH2O several times and dried.
Dynamic light scattering
To determine the size of MNPs and virus-MNP complexes in various aqueous and buffer
conditions, samples were measured using a DynaPro Titan Light Scattering Instrument.
Samples were loaded in 20 uL cuvettes and run at 10% power (to prevent saturated counts).
Measurements were collected at 10 s intervals. Each sample was run 10 times.
Magnetometer measurements
Cells were harvested and lysed with cell lysis buffer (PBS + 0.1% Triton X-100 + 1% SDS).
Transverse relaxation times of cell lysates were measured using a Bruker 0.47T minispec
q20 (Bruker Optics) at 40°C. Relaxivity was calculated by measuring T2 relaxation times of
samples and plotting the inverse relaxation times against the iron concentration of the
sample and taking the slope.
Targeting in vitro
For experiments involving cell lines, 100,000 cells were seeded in 24-well tissue culture
plates (BD Biosciences) in appropriate tissue culture media. Cell lines were incubated with
virus-templated, non-functionalized or functionalized MNPs in PBS, depending on the
experiment. Samples were incubated at 37°C for 1, 4, or 24 h and then collected in 300 uL
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lysis buffer (PBS supplemented with 1% SDS and 0.1% Triton X-100) and incubated on ice
for 30 minutes before being measured by table-top relaxometer or flow cytometry.
Flow cytometry
For cell targeting experiments in vitro, MNPs, M13-MNP, and M13-SBP-MNP were
labelled with either 10 ug mL−1 Alexa Fluor 680 or Alexa Fluor 488 succinimidyl ester
(Life Technologies). After conjugation, samples were dialyzed to remove unconjugated dye
using a dialysis bag with a 12,000-14,000 molecular weight cut-off (Spectrum Labs). Cells
incubated with samples were washed and collected using trypsin-EDTA (Life
Technologies). Collected cells were neutralized with complete media with 10% FBS and
washed twice with 2% FBS in PBS. Cells were run on FACScalibur (Becton Dickinson).
Uptake as measured by mean fluorescence was analysed from 10,000 gated events. Samples
were run in triplicate.
Targeting in vivo
DU145 and C4-2B cells were trypsinized from tissue culture plates and collected. A total of
2×106 DU145 and C4-2B cells each were resuspended in PBS. C4-2B cells were
resuspended in a 1:1 solution of Matrigel (BD Biosciences) to PBS, and cell lines were
injected subcutaneously above both flanks of 7- to 9- week-old athymic nu/nu mice (Charles
River) weighing ~30 g, with n = 5 for each cohort. Tumours were grown 3-5 weeks to ~3-5
mm diameter for in vivo targeted imaging experiments. Tumoured mice were injected with
1×1012 plaque-forming units of M13-SBP-MNP in PBS (with ~20 mg kg−1 iron
concentration) via tail-vein and imaged 24 h post-injection using a 7T Pharmascan MR
small animal scanner (Bruker). Samples were imaged with weighted T2*. Images were
obtained with TE = 10 ms. Images were processed and analysed with OsiriX imaging
software. To quantify the pixel intensity of mice injected with M13-SBPMNP probe bearing
either C4-2B or DU145 tumours, images were collected at the same imaging depth (same z
plane or depth) of each mouse and regions of interest (ROI) with equivalent areas (~0.1
cm2) were drawn around the tumoured areas. The pixel intensity was calculated and
normalized to the area from the ROI.
Correlative Histology
After imaging, animals were sacrificed and tumours were excised and frozen in optimal
cutting temperature (OCT). Serial frozen sections were stained with H&E or for the
presence of iron using Perl’s reagent. Sections were stained for SPARC expression using
antibody against SPARC (R&D Systems). Images were taken with an Olympus IX51
inverted microscope at various magnifications and processed with camera software.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Schematic and targeting in vitro of M13-templated magnetic nanoparticles for MR
imaging
a, Schematic of M13 (yellow) with SPARC binding peptide displayed on p3 protein of virus
(in pink). p8 proteins displaying triglutmate motif for multivalent assembly and display of
iron oxide nanocrystals (denoted as black circles) along the viral coat. b, Cell-specific
targeting of various concentrations of M13-SBP-MNP against DU145 (low SPARC
expression) and C4-2B (SPARC expressing) cell lines. For all work, uptake measured by T2
relaxation times. Error bars represent standard errors (n = 3).
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Figure 2. Material characterization of MNPs and M13-templated MNPs
TEM (top row), stability (middle row), and dynamic light scattering (DLS) (bottom row) of
synthesized and assembled iron oxide nanoparticles along the p8 major coat of M13 (left
and right column, respectively). TEM of MNPs and M13-templated MNPs with higher
resolution images in inset. For stability, samples were resuspended in PBS (left), serum
(fetal bovine serum (FBS), middle) and tissue culture media (right). For DLS, MNPs were
water-solubilized with NH2-PEG-DSPE (2000) and samples were run on a DynaPro Titan
Light Scattering instrument at 10% power. Samples were run with n = 10.
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Figure 3. Targeting in vivo using MRI and correlative histology
a,b, MR scans of mice with C4-2B tumours (encircled) pre-injection and 24 h post-injection,
respectively, with M13-SBP MNP. c,d, MR scans of DU145 control tumours (circled) pre-
injection and 24 h post-injection with probe, respectively. Note the maintenance of the
bright image of the tumour (circled) in DU145 pre- to post-injection, whereas a post-
injection dark contrast against the pre-injection bright MR image is observed in C4-2B
(circled). All tumours formed subcutaneously in athymic nude mice and imaged using 7 T
small animal MR scanner. e, Tumour images were quantified for pixel intensities.
Equivalent regions of interest (ROI) were marked around all tumours ~ 5 mm in diameter,
and pixel intensity of the image was quantified using OsiriX imaging software and
normalized to the area of the ROI. All images of tumours had similar areas and were taken
from the same imaging depth from all mice (n = 5 for each group) to enable accurate
comparison. Error bars represent standard error (n = 5). f, Histology for M13-SBP-MNP
tumour accumulation. Tumours were sectioned and stained with H&E and Perl’s reagent for
the presence of iron. Tumour sections were also stained for SPARC expression using an
anti-human SPARC antibody. Sections in blue suggest areas of iron oxide nanoparticle
localization. Blue staining is present around the stroma in C4-2B sections (top row, middle
column). There is no blue present in the DU145 control (bottom row, middle column). There
is co-localization of SPARC expression (top row, far right) with iron accumulation in C4-2B
tumours; there is no SPARC expression in DU145 tumours (bottom row, far right). All
panels are at the same scale.
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Figure 4. Amplified targeting in vitro
a, Left: schematic of SPARC-binding peptide ligand targeting of nanoparticles to targets via
multivalent interactions. Right: M13 assembles multiple nanoparticles along its coat to
deliver a higher cargo of nanoparticles per SPARC target than the ligand functionalized
nanoparticles (left). b, C4-2B uptake of M13-SBP-MNP or functionalized MNPs with two
different SBP concentrations as measured by fluorescence, at 1 h and 4 h respectively. c,
Comparison of targeting of C42B using M13-SBP-MNP compared with peptide-
functionalized MNPs (SBP-MNP), as measured by transverse relaxation. All error bars
represent standard errors (n = 3).
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Table 1
Relaxivities of various MR contrast agents at 0.47T, 40°C
Contrast agent Relaxivity (R2) [mMs]−1
Monocrystalline iron oxide nanoparticle
(MION-46)
−34.819
Cross-linked iron oxide (CLIO) 4831
Ferumoxtran 35.320,32
Ferumoxide-Feridex 10722
Iron oxide nanoparticles (MNPs) 65.1
M13-templated MNPs 58.7
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